What is Structure Based Design?
Structure Based Design, Inc. (SBD) operates at the intersection of advanced structural biology and pharmaceutical research. The company provides critical infrastructure for drug development, specializing in Macromolecule X-Ray Crystallography, Fragment-based Crystallographic Screening, and high-precision Protein Biochemistry. By offering comprehensive services such as crystal structure determination, protein manufacturing, and assay development, SBD serves as a vital partner for pharmaceutical and biotechnology entities aiming to streamline their therapeutic pipelines. Their technical proficiency in mapping molecular interactions allows clients to navigate complex drug discovery processes with greater efficiency and scientific rigor.
How much funding has Structure Based Design raised?
Structure Based Design has raised a total of $50K across 1 funding round:
Debt
$50K
Debt (2021): $50K with participation from PPP
Key Investors in Structure Based Design
PPP
Public-Private Partnership
What's next for Structure Based Design?
With the infusion of this recent capital, Structure Based Design is poised to scale its operational capacity and enhance its technological suite. The strategic focus will likely center on expanding its laboratory infrastructure to meet the growing demand for high-throughput crystallographic screening. As the pharmaceutical industry continues to prioritize precision medicine and targeted therapies, SBD's role as a specialized service provider becomes increasingly central. The company is expected to leverage these resources to deepen its research capabilities, potentially integrating new computational modeling tools to complement its existing wet-lab expertise, thereby maintaining its competitive edge in the high-stakes biotech services market.
See full Structure Based Design company page
